I-Mab Announces Upcoming Participation at October Conferences

Rhea-AI Summary

I-Mab (Nasdaq: IMAB) announced its participation in two upcoming conferences in October. The J.P. Morgan Global Healthcare Conference, held from October 12-13 in Shanghai, and the virtual Jefferies China Biotech Summit on October 26, 2021, will feature key management personnel including the founder and CEO. I-Mab focuses on the development of innovative biologics, particularly in immuno-oncology, and is transitioning towards becoming a fully integrated global biopharmaceutical company with extensive R&D and manufacturing capabilities.

Positive

• Participation in J.P. Morgan Global Healthcare Conference and Jefferies China Biotech Summit may increase visibility and investor interest.
• Company is progressing towards becoming a fully integrated global biopharmaceutical entity.

Negative

• None.

SHANGHAI and GAITHERSBURG, Md., Oct. 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in October. Details of the conferences are as follows:

J.P. Morgan Global Healthcare Conference

One-on-one and small group meetings: October 12-13, 2021

Location: Ritz-Carlton Hotel, Shanghai

Management participants: Dr. Jingwu Zang, Founder, Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, Mr. Tianyi Zhang, Executive Director Investor Relations, Mr. Tyler Ehler, Senior Director Investor Relations and Phoebe Peng, Associate Director Investor Relations

For more information, please contact your J.P. Morgan representative.

Jefferies China Biotech Summit (Virtual)

One-on-one and small group meetings: October 26, 2021

Management participants: Dr. Jingwu Zang, Founder, Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, Mr. Tianyi Zhang, Executive Director Investor Relations, Mr. Tyler Ehler, Senior Director Investor Relations and Phoebe Peng, Associate Director Investor Relations

For more information, please contact your Jefferies representative.

About I-Mab

I-Mab (Nasdaq: IMAB) is an innovation-driven global biotech company focusing on discovery, development and soon commercialization of novel and highly differentiated biologics in immuno-oncology therapeutic area. The Company's mission is to bring transformational medicines to patients around the world through drug innovation. I-Mab's globally competitive pipeline of more than 15 clinical and pre-clinical stage drug candidates is driven by its internal R&D capability and global licensing partnerships, based on the Company's unique Fast-to-Proof-of-Concept and Fast-to-Market pipeline development strategies. The Company is now rapidly progressing from a clinical stage biotech company to a fully integrated global biopharmaceutical company with cutting-edge global R&D capabilities, a world-class GMP manufacturing facility and commercialization capability. I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou, Guangzhou, Lishui and Hong Kong in China, and Maryland and San Diego in the United States. For more information, please visit http://ir.i-mabbiopharma.com and follow I-Mab on LinkedIn, Twitter and WeChat.

For more information, please contact:

I-Mab

Jielun Zhu, Chief Financial Officer
E-mail: jielun.zhu@i-mabbiopharma.com
Office line: +86 21 6057 8000

Gigi Feng, Chief Communications Officer
E-mail: gigi.feng@i-mabbiopharma.com
Office line: +86 21 6057 5709

Investor Inquiries:

The Piacente Group, Inc.
Emilie Wu
E-mail: emilie@thepiacentegroup.com
Office line: + 86 21 6039 8363

View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-announces-upcoming-participation-at-october-conferences-301389534.html

SOURCE I-Mab

FAQ

What conferences is I-Mab participating in October 2021?

I-Mab is participating in the J.P. Morgan Global Healthcare Conference on October 12-13 and the Jefferies China Biotech Summit on October 26, 2021.

Who are the management participants in I-Mab's upcoming conferences?

Management participants include Dr. Jingwu Zang, Dr. Joan Huaqiong Shen, Mr. Jielun Zhu, Mr. Tianyi Zhang, Mr. Tyler Ehler, and Ms. Phoebe Peng.

What is I-Mab's focus in biopharmaceuticals?

I-Mab focuses on the discovery, development, and commercialization of novel biologics, particularly in the immuno-oncology therapeutic area.

What is the significance of I-Mab's participation in these conferences?

Participation in these conferences may enhance I-Mab's visibility and attract potential investors, showcasing its innovative pipeline and growth strategies.